MetaCap

Arcturus Therapeutics (ARCT) vs Keros Therapeutics (KROS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcturus Therapeutics (ARCT) has outperformed Keros Therapeutics (KROS) over the past year, gaining 19.0% versus a loss of 36.3%. Over five years, KROS leads with a -80.2% price change compared with -81.3% for ARCT. Keros Therapeutics is the larger company by market cap ($217.4 million vs $214.7 million), about 1.0 times the size.

Keros Therapeutics converts more of its revenue into profit, with a net margin of 35.7% versus -80.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARCT+19.01%KROS-36.29%
+181%+62%-58%
Nov 21, 20251 yearNov 20, 2026
ARCT-79.56%KROS-81.48%
+35%-28%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARCT versus KROS key metrics
MetricARCTKROS
Share price$7.45$11.08
Market cap$214.73M$217.44M
1-day change-1.97%-2.72%
YTD return+21.53%-45.58%
1-year return+19.01%-36.29%
5-year return-81.32%-80.25%
EPS (TTM)$-3.10$-2.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$82.03M$243.86M
Revenue growth (YoY)-46.14%—
Net income (latest FY)$-65.78M$87.01M
Operating margin-92.96%27.71%
Net margin-80.19%35.68%
52-week high$17.96$22.55
52-week low$5.50$8.98
Distance from 52-week high-58.52%-50.86%
Analyst consensusstrong_buybuy
Avg. price target upside+218.12%+78.97%
Average volume851.45K196.50K
Shares outstanding28.82M19.62M
Employees10687
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARCT has outperformed KROS by 55.3 percentage points over the past year.
  • Keros Therapeutics is more profitable, keeping 35.7 cents of every revenue dollar as net income versus -80.2 cents for Arcturus Therapeutics.

About Arcturus Therapeutics

ARCT stock →

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Keros Therapeutics

KROS stock →

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

ARCT vs KROS FAQ

Which is bigger, Arcturus Therapeutics or Keros Therapeutics?

Keros Therapeutics (KROS) is larger, with a market capitalization of $217.44M compared with $214.73M for Arcturus Therapeutics (ARCT).

Which stock has performed better over the past year, ARCT or KROS?

ARCT returned +19.01% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.

Are Arcturus Therapeutics and Keros Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons